PMI
Picard Medical, Inc.2.3000
-0.1300-5.35%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
169.51MP/E (TTM)
-Basic EPS (TTM)
-0.44Dividend Yield
0%Recent Filings
8-K
Rings NYSE bell
Picard Medical rang the NYSE opening bell on December 18, 2025, celebrating its transition to public markets. The event highlights commitment to advancing the SynCardia Total Artificial Heart, including the fully implantable Emperor system, building on over 2,100 implants worldwide. Public status bolsters platform development. Forward-looking statements carry risks per SEC filings.
8-K
Record 8-year SynCardia survival
Picard Medical celebrated a world-record patient surviving over eight years—2,900 days—on its SynCardia Total Artificial Heart, implanted December 9, 2017, in Serbia. This Serbian case, alongside four other top long-term supports from the same hospital, underscores the device's durability for end-stage heart failure. Serbia leads globally. Picard advances its next-gen Emperor heart.
8-K
Emperor TAH data unveiled
Picard Medical presented in vitro and first in vivo porcine data on its Emperor Total Artificial Heart at the ISMCS meeting on December 4, 2025. The device replicates the FDA-approved SynCardia TAH's preload sensitivity and afterload independence using identical blood-contacting components but electromechanical actuation. Emperor matched STAH performance at 125 BPM. Sets stage for chronic animal studies.
8-K
CEO presents heart data
Picard Medical's CEO Patrick NJ Schnegelsberg presents Emperor Total Artificial Heart data at CSI Focus D-HF conference December 6, 2025, in Frankfurt. The event spotlights device therapies for heart failure, drawing global experts. CEO attends key session. Presentation underscores Picard's push into fully implantable tech.
8-K
Emperor Heart data at ISMCS
Picard Medical announced Duffy Elmer will present in vitro benchtop data on its fully implantable Emperor Total Artificial Heart at ISMCS 2025 in Vienna on December 4. The next-gen device ditches external drivers for better patient mobility. Data showcases hemocompatibility. Forward-looking claims carry risks per filing.
AMIX
Autonomix Medical, Inc.
0.63-0.03
BDMD
Baird Medical Investment Holdin
1.37+0.02
EW
Edwards Lifesciences Corporatio
85.32+1.94
HSCS
HeartSciences Inc.
2.31-0.16
IRMD
iRadimed Corporation
96.87-0.15
MDNC
MEDINOTEC INC
5.00+0.00
MODD
Modular Medical, Inc.
0.34-0.03
NUMD
Nu-Med Plus Inc.
0.02-0.01
PIII
P3 Health Partners Inc.
4.59-0.36
PMEDF
PREDICTMEDIX AI INC.
0.05-0.00